Free Coupon Code GLP-1 & GIP Drugs:Ozempic, Wegovy-Obesity & Diabetes Therapy 100% OFF

Udemy Free coupon code for GLP-1 & GIP Drugs:Ozempic, Wegovy-Obesity & Diabetes Therapy course taught by Dr. Amogh Gopinathan Nair, which has 1,012 students and is rated 5.0 out of 0 votes. This course is about 1 hour(s) in English and was updated on December 04, 2025. You can use this Udemy course with a free certificate and find the coupon at the bottom of this page.

Master the science and clinical applications of GLP-1–based therapies like Ozempic, Wegovy, and Mounjaro

GLP-1 receptor agonists and dual GIP/GLP-1 agonists have transformed the treatment of type 2 diabetes, obesity, and cardiometabolic disorders.

Drugs like Ozempic, Wegovy, and Mounjaro are no longer just glucose-lowering agents; they are reshaping obesity management, cardiovascular risk reduction, and even liver disease therapy.

This course is about GLP-1 & GIP Drugs like Ozempic, Wegovy, and Mounjaro used in Obesity & Diabetes Therapy, and is designed to give you a complete, mechanism-driven understanding of how incretin hormones work, why their biology is so powerful, and how modern therapeutics harness these pathways to benefit the people in need.

You will explore the molecular mechanisms of incretin receptors, pancreatic regulation, and multi-organ effects, and then connect this knowledge to real-world therapeutic applications.

Whether you are in biotech research, pharmacy, medicine, or academia, this course bridges cutting-edge molecular biology with practical pharmacology and clinical insight.

By the end, you’ll be able to:

• Explain the physiology of GLP-1 and GIP and their complementary roles in glucose regulation

• Understand how receptor signaling differences translate into therapeutic outcomes

• Evaluate how incretin therapies impact multiple organs: brain, gut, adipose tissue, and liver

• Analyze clinical trial data on HbA1c reduction, weight loss, and cardiovascular protection

• Appreciate the evolution from GLP-1 analogues to dual agonists, and where the field is going